Thyrocare Technologies Ltd

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 10(6) of SEBI (SAST) Regulations, 2011, regarding the amalgamation of Docon Technologies Private Limited with API Holdings Limited, resulting in API acquiring 51.02% of Thyrocare's paid-up share capital.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has published newspaper advertisements regarding the transfer of equity shares to the Investor Education and Protection Fund, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from API Holdings Ltd, indicating a potential change in shareholding or acquisition.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced that the Hon'ble NCLT, Mumbai Bench, has sanctioned the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited. The Scheme shall become operative upon the Effective Date, which is the date when all conditions precedent are completed or duly waived.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from Catalyst Trusteeship Limited, confirming the complete discharge of all obligations under the Non-Convertible Debentures (NCDs) and the Transaction Documents. The NCDs, aggregating to INR 1,700 crore, were secured by a pledge of equity shares representing 60.92% of the equity share capital of the Company held by Docon. Upon full redemption and repayment of the NCDs, the pledge has been fully released.

Thyrocare Technologies Ltd

Catalyst Trusteeship Limited, acting as Debenture Trustee, has released the pledge on 7,94,69,696 equity shares of Thyrocare Technologies Ltd after the full repayment and redemption of Non-Convertible Debentures.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd & PACs.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from Docon Technologies Private Limited, its promoter, regarding the release of a pledge over 7,94,69,696 equity shares of the company. The pledge was created due to the repayment of non-convertible debentures issued by API Holdings Limited, the ultimate holding company of the company.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from HSBC Mutual Fund, indicating a potential change in shareholding.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd on August 13, 2026.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd and PAC regarding a potential acquisition.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Docon Technologies Pvt Ltd.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of pledge on 7,94,69,696 equity shares of the company. The pledge was created to secure the obligations of API Holdings Limited, the holding company, in respect of facilities availed by API through the issuance of non-convertible debentures. The debentures have been fully redeemed and repaid, resulting in the release of the pledge.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from ICICI Prudential Mutual Fund, indicating a potential change in shareholding.

Thyrocare Technologies Ltd

Catalyst Trusteeship Limited, acting as Debenture Trustee for API Holdings Limited, has released a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited, resulting in a 10.99% stake in the company.

Thyrocare Technologies Ltd

Docon Technologies Private Limited, a wholly-owned subsidiary of API Holdings Limited and a promoter of Thyrocare Technologies Limited, has sold 1,57,69,696 equity shares of Thyrocare, representing approximately 9.9% of the total paid-up share capital, reducing the promoter shareholding from 60.92% to 51.02%.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd's promoter, Docon Technologies Private Ltd, has released a pledge on 1,75,00,000 equity shares of the company, held by Docon, which were pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure from its promoter, Docon Technologies Private Limited, stating that it has sold 1,57,69,696 equity shares of the company through market trades, representing approximately 9.90% of the total paid-up equity share capital. This has reduced the promoter's shareholding from 60.92% to 51.02%.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 1,75,00,000 equity shares of the company. The pledge was released by Catalyst Trusteeship Limited on August 11, 2026, and the promoter has submitted the required disclosures under SEBI regulations.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has released the transcript of its Q1 FY27 earnings conference call, which was held on July 23, 2026. The company's management discussed its quarterly highlights, including its growth in Africa and its recognition as India's most trusted customer-focused diagnostic brand.